Hans Stieltjes
Johnson & Johnson (United States)(US)Janssen (Belgium)(BE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Biosimilars and Bioanalytical Methods, Pharmacogenetics and Drug Metabolism, Pancreatic function and diabetes, Pharmaceutical studies and practices
Most-Cited Works
- → Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer(2015)102 cited
- A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.(1997)
- → Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ‐54861911, a potent oral BACE inhibitor(2016)59 cited
- → Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor(2015)49 cited
- → Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants(2014)46 cited
- → Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants(2014)35 cited
- → Oxygen and nitrogen heterocycles by intramolecular magnesium- and zinc-ene reactions; Methylenecyclopentanes by Pd(0) - catalyzed isomerization of 5-(bromozincmethyl)-3-methyleneoxacycloalkanes(1987)33 cited
- → Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin(2014)32 cited
- → Single‐dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment(2013)31 cited
- → Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects(2015)30 cited